About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline

LOG IN
LOG IN


1 1 (March 29, 2021)

handle is hein.crs/govecvh0001 and id is 1 raw text is: Congressional *.Research Service informing the I gislative debate since 1914___________________ Domestic Funding for COVID-19 Vaccines: An Overview Updated March 29, 2021 To date, the U.S. Food and Drug Administration (FDA) has authorized for emergency use three Coronavirus Disease 2019 (COVID-19) vaccines; additional vaccines may become available within months. Federal efforts to develop, manufacture, regulate, purchase, and distribute vaccines have involved a number of agencies. Under the Trump Administration, such efforts were largely organized under Operation Warp Speed (OWS) led by the Department of Health and Human Services (HHS) and the Department of Defense (DOD). Coordinated interagency efforts continue under the Biden Administration. Many aspects of federal domestic vaccine efforts have thus far been funded by appropriations in COVID- 19 relief acts, especially funding to U.S. Public Health Service (PHS) agencies and accounts. The following provides an overview of appropriations for selected domestic COVID-19 vaccine related activities. (With the exception of the mandatory funding provided by the American Rescue Plan Act of 2021 (ARPA), all funding amounts discussed below are classified as discretionary.) The following is meant to inform a general understanding of available funding, but may not capture every federal account that can be used for vaccine-related activities. In general, many of the HHS appropriations are available for multiple years or until expended, and some of the funding is transferrable between accounts by the HHS Secretary. This product does not address financing for vaccine administration, global vaccination funding, or related allocations and spending. Research and Development, Regulation, Manufacture, and Purchase COVID-19 vaccine research and development (R&D), regulation, manufacture, and purchase have been largely supported by a collaboration among several federal agencies, including the National Institutes of Health (NIH), the Biomedical Advanced Research and Development Authority (BARDA), FDA, DOD, and others (formerly OWS). Six vaccines were chosen for coordinated federal support under OWS. Some vaccine R&D has been supported by NIH, BARDA, and DOD separately from the OWS efforts. For R&D, funding has been provided to accounts at NIH, DOD, and the Public Health and Social Services Emergency Fund (PHSSEF; parent account for BARDA) for COVID-19 related R&D, including vaccine R&D. In addition, over $50 billion in PHSSEF funding has been made available until September 24, 2024 for a broad set of medical countermeasures and surge capacity purposes, including for the Congressional Research Service https://crsreports. congress.gov IN11556 CRS INSIGHT Prepared for Members and Committees of Congress